Russian MedicineRussian MedicineРоссийский медицинский журнал0869-21062412-9100Eco-Vector3833410.18821/0869-2106-2016-22-1-36-42ArticlesСтатьиResearch ArticleThe perspectives of application of statins under pulmonary hypertensionПерспективы применения статинов при легочной гипертензииBaksheevVladimir I.БакшеевВладимир Иванович

MD, PhD, DSc

доктор мед. наук, начальник отделения

baksheevld@mail.ruKolomoetzN. MКоломоецН. М

The consultative diagnostic polyclinic

Консультативно-диагностическая поликлиника

ShklovskiyB. LШкловскийБ. ЛOynotkinovaO. ShОйноткиноваО. ШThe A.A. Vishnevskii third central military clinical hospital of the Ministry of defense of the Russian FederationФГБУ «3-й центральный военный клинический госпиталь им. А.А. Вишневского» Министерства обороны Российской Федерации"The P.V. Mandrik Medical training research clinical center" of the Ministry of defense of the Russian FederationФКУ «Медицинский учебно-научный клинический центр им. П.В. Мандрыка» Министерства обороны Российской Федерации15022016221VOL 22, NO1 (2016)ТОМ 22, №1 (2016)364221072020Copyright ©; 2016, Eco-VectorCopyright ©; 2016, ООО "Эко-Вектор"2016Eco-VectorООО "Эко-Вектор"https://medjrf.com/0869-2106/article/view/38334

The present publications' review considers perspectives of application of statins under pulmonary hypertension. Nowadays, there are quite encouraging experimental data concerning positive versatile effect of statins on lesser blood circulation. The results of study of this issue with participation of patients are singular and continue to be controversial still. The clinical substantiation of application of new pharmaceuticals effecting molecular mechanisms of pathogenesis of pulmonary hypertension (re-modeling, endothelial dysfunction, function of right ventricle) requires carrying out of large investigations placebo-controlled by design and statistical processing. Precisely in this context the application of statins is of interest as potentially strategic direction in treatment of pulmonary hypertension.

В данном обзоре литературы рассматриваются перспективы применения статинов при легочной гипертензии. На сегодняшний день имеются весьма обнадеживающие экспериментальные данные о положительном многогранном воздействии статинов на малый круг кровообращения. Результаты изучения этого вопроса с участием пациентов единичны и пока остаются противоречивыми. Для клинического обоснования применения новых препаратов, воздействующих на молекулярные механизмы патогенеза легочной гипертензии (ремоделирование, эндотелиальную дисфункцию, функцию правого желудочка), необходимо проведение крупных плацебо-контролируемых по дизайну и статистической обработке исследований. Именно в этом контексте применение статинов представляет интерес как потенциально стратегическое направление в лечении легочной гипертензии.

pulmonary hypertensionstatinsclinical investigationcardiorespiratory pathologyheart diseaseslungs diseasesright ventricleлегочная гипертензиястатиныклинические исследованиякардиореспираторная патологиязаболевания сердцазаболевания легкихправый желудочекДиагностика и лечение легочной гипертензии. Всероссийское научное общество кардиологов. Кардиоваскулярная терапия и профилактика. 2007; 6 (6 S2): 4-19.Чазова И.Е., Мартынюк Т.В., ред. Легочная гипертензия. М.: Практика; 2015.Simonneau G., Gatzoulis M.A., Adatia I., Celermajer D., Denton C., Ghofrani A. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62(25 Suppl.): D34-41.Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V. et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 2006; 173(9): 1023-30.Peacock A.J., Murphy N.F., McMurray J.J., Caballero L., Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 2007; 30(1):104-9.Vachiery J.L., Adir Y., Barbera J.A., Champion H.C., Coghlan J.G., Cottin V. et al. Pulmonary hypertension due to left heart disease. J. Am. Coll. Cardiol. 2013; 62: D100-8.Ghio S., Gavazzi A., Campana C., Inserra C., Klersy C., Sebastiani R. et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J. Am. Coll. Cardiol. 2001; 37(1): 183-8.Guazzi M., Borlaug B.A. Pulmonary hypertension due to left heart disease. Circulation. 2012; 126(8): 975-90.Minai O.A., Chaouat A., Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest. 2010; 137(6 Suppl.): 39S-51S.Беленков Ю.Н., Преображенский Д.В., Сидоренко Б.А., Батыралиев Т.А. Легочная гипертензия и правожелудочковая сердечная недостаточность. М.: Ньюдиамед; 2009.Lettieri C.J., Nathan S.D., Barnett S.D., Ahmad S., Shorr A.F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006; 129(3): 746-52.Sajkov D., McEvoy R.D. Obstructive sleep apnea and pulmonary hypertension. Prog. Cardiovasc. Dis. 2009; 51(5): 363-70.Kessler R., Chaouat A., Schinkewitch P., Faller M., Casel S., Krieger J. et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest. 2001; 120(2): 369-76.Lang I.M., Pesavento R., Bonderman D., Yuan J.X. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur. Respir. J. 2013; 41(2): 462-8.Galiè N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart. J. 2015; pii: ehv317. PMID: 26320113.Бакшеев В.И., Коломоец Н.М., Шкловский Б.Л. Гипертоническая болезнь и ишемическая болезнь сердца - проблема врача и пациента. 2-е изд. М.: БИНОМ; 2015.Peacock A. Pulmonary hypertension. Eur. Respir. Rev. 2013; 22(127): 20-5.Nishimura T., Faul J.L., Berry G.J., Vaszar L.T., Qiu D., Pearl R.G. et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 2002; 166(10): 1403-8.Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000; 6(9): 1004-10.Abe K., Shimokawa H., Morikawa K., Uwatoku T., Oi K., Matsumoto Y. et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 2004; 94(3): 385-93.Laufs U., Fata V.L., Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated downregulation of endothelial nitric oxide synthase. J. Biol. Chem. 1997; 272(50): 31725-9.Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M. et al. HMG-CoA reductase inhibitors increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 2001; 108(3): 391-7.Girgis R.E., Li D., Zhan X., Garcia J.G., Tuder R.M., Hassoun P.M. et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. Heart Circ. Physiol. 2003; 285(3): H938-45.Nishimura T., Vaszar L.T., Faul J.L., Zhao G., Berry G.J., Shi L. et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003; 108(13): 1640-5.Girgis R.E., Mozammel S., Champion H.C., Li D., Peng X., Shimoda L. et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 292(5): L1105-10.Carlin C., Celnick D.F., Pak O., Wadsworth R., Peacock A.J., Welsh D.J. Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension. Am. J. Respir. Cell. Mol. Biol. 2012; 47(2): 140-8.Liu Z.Q., Liu B., Yu L., Wang X.Q., Wang J., Liu H.M. Simvastatin has beneficial effect on pulmonary artery hypertension by inhibiting NF-κB expression. Mol. Cell. Biochem. 2011; 354(1-2): 77-82.Li J., Li J.J., He J.G., Nan J.L., Guo Y.L., Xiong C.M. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway. Cardiovasc. Ther. 2010; 28(1): 8-14.Ali O., Growcott E. J., Wilkins M. R., Wharton J. Anti-proliferative and pro-apoptotic effects of statins in human pulmonary artery smooth muscle cells. Circulation. 2006; 114 (18 Supl.): 81.Ali O.F., Growcott E.J., Butrous G.S., Wharton J. Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells. Respir. Res. 2011; 12: 137.Hilgendorff A., Muth H., Parviz B., Staubitz A., Haberbosch W., Tillmanns H. et al. Statins differ in their ability to block NFkB activation in human blood monocytes. Int. J. Clin. Pharmacol. Ther. 2003; 41(9): 397-401.Guignabert C., Raffestin B., Benferhat R., Raoul W., Zadigue P., Rideau D. et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005; 111(21): 2812-9.Duarte J.D., Hanson R.L., Machado R.F. Pharmacologic Treatments for Pulmonary Hypertension. Future Cardiol. 2013; 9(3): 335-49.Laudi S., Trump S., Schmitz V., West J., McMurtry I.F., Mutlak H. et al. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 293(3): L630-8.Sun X., Ku D.D. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am. J. Physiol. Heart. Circ. Physiol. 2008; 294(2): H801-9.Wang S.H., Liu S., Yang J.H., Wang Z.Z., Li J., Hou W.W. Protective effects of beraprost plus simvastatin on monocrotaline-induced pulmonary arterial hypertension in rats. Zhonghua Yi Xue Za Zhi. 2013; 93(22): 1691-5.Zhao L., Sebkhi A., Ali O., Wojciak-Stothard B., Mamanova L., Yang Q. et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur. Respir. J. 2009; 34(4): 948-57.Kuang Е., Wang J., Pang B., Huang X., Burg E.D., Yuan J.X. et al. Combination of Sildenafil and Simvastatin Ameliorates Monocrotaline-induced Pulmonary Hypertension in Rats. Pulm. Pharmacol. Ther. 2010; 23(5): 456-64.Guttierrez C.A. Sildenafil-simvastatin interaction: possible cause of rhabdomyolisis? Am. Fam. Physician. 2001; 63(4): 636-7.Xie L., Lin P., Xie H., Xu C. Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats. Clin. Exp. Hypertens. 2010; 32(8): 547-54.McMurtry M.S., Bonnet S., Michelakis E.D., Bonnet S., Haromy A., Archer S.L. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 293(4): L933-40.Hu H., Sung A., Zhao G., Shi L., Qiu D., Nishimura T. et al. Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem. Biophys. Res. Commun. 2006; 339(1): 59-64.Eshtehardi P., Mojadidi M. K., Goodman-Meza D., Khosraviani K., Pamerla M., Zolty R. Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. Circulation. 2014; 130 (Suppl. 2): A11717.Barreto A.C., Maeda N.Y., Soares R.P., Cicero C., Lopes A.A. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. Braz. J. Med. Biol. Res. 2008; 41(8): 657-63.Kao P. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest. 2005; 127(4): 1446-52.Крахмалова Е.О., Гетман Е.А., Калашник Д.Н. Динамика клинической симптоматики легочной гипертензии у пациентов с ХОЗЛ и сопутствующей ИБС на фоне терапии статинами. Український пульмонологічний журнал. 2014;1: 39-44.Zeng W.J., Xiong C.M., Zhao L., Shan G.L., Liu Z.H., Xue F. et al. Atorvastatin in Pulmonary Arterial Hypertension (APATH) Study Group. Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur. Respir. J. 2012; 40(1): 67-74.Kawut S.M., Bagiella E., Lederer D. J., Shimbo D., Horn E.M., Roberts K.E. et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation. 2011; 123(25): 2985-93.Wilkins M.R., Ali O., Bradlow W., Wharton J., Taegtmeyer A., Rhodes C.J. et al. Simvastatin as a treatment for pulmonary hypertension trial. Am. J. Respir. Crit. Care Med. 2010; 181(10): 1106-13.Rich S. Future of clinical trials for pulmonary hypertension. Circulation. 2011; 123(25): 2919-21.Rylova A., Arutyunov G., Rylova N. Effect of long-term simvastatin therapy on pulmonary artery pressure in patients with severe CHF. Eur. J. Heart Failure. 2006; 5 (Suppl. 1): 176.Rylova A., Rylova N., Arutyunov G. Effects of statins in pulmonary hypertension in patients with severe chronic heart failure. Eur. J. Heart Failure. 2006; 5(Suppl. 1): 176.Шабанов Е.А. Эндотелиальная дисфункция, легочная гипертензия и их коррекция у больных ишемической болезнью сердца в сочетании с хронической обструктивной болезнью легких: Дисс. … канд. мед. наук. Курск; 2012.Lee T.M., Chen C.C., Shen H.N., Chang N.C. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin. Sci. (Lond.) 2009; 116(6): 497-505.Young R.P., Hopkins R.J. Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. Expert Rev. Respir. Med. 2013; 7(5): 533-44.Li D.H., Wang C.J., Zhang S.S., Mao H. Clinical study on simvastatin treatment of pulmonary hypertension in patients with coal worker's pneumoconiosis. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2011; 29(3): 230-1.Reed R.M., Iacono A., DeFilippis A., Jones S., Eberlein M., Lechtzin N. et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD. 2011; 8(2): 96-102.Kaczmarek P., Sładek K., Skucha W., Rzeszutko M., Iwaniec T., Dziedzina S. et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol. Arch. Med. Wewn. 2010; 120(1-2): 11-7.Moosavi S.A., Raji H., Faghankhani M., Yazdani R., Esmaeili M. Evaluation of the effects of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive pulmonary diseases: a randomized controlled trial. Iran. Red. Crescent. Med. J. 2013; 15(8): 649-54.Watson G., Oliver E., Zhao L., Wilkins M.R. Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers). Handb. Exp. Pharmacol. 2013; 218: 531-48.